FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4323352010> ?p ?o ?g. }

• W4323352010 endingPage "107" @default.
• W4323352010 startingPage "97" @default.
• W4323352010 abstract "Ending the global COVID-19 pandemic requires efficacious therapies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nevertheless, the emerging Omicron sublineages largely escaped the neutralization of current authorized monoclonal antibody therapies. Here we report a tetravalent bispecific antibody ISH0339, as a potential candidate for long-term and broad protection against COVID-19.We report here the making of ISH0339, a novel tetravalent bispecific antibody composed of a pair of non-competing neutralizing antibodies that binds specifically to two different neutralizing epitopes of SARS-CoV-2 receptor-binding domain (RBD) and contains an engineered Fc region for prolonged antibody half-life. We describe the preclinical characterization of ISH0339 and discuss its potential as a novel agent for both prophylactic and therapeutic purposes against SARS-CoV-2 infection.ISH0339 bound to SARS-CoV-2 RBD specifically with high affinity and potently blocked the binding of RBD to the host receptor hACE2. ISH0339 demonstrated greater binding, blocking and neutralizing efficiency than its parental monoclonal antibodies, and retained neutralizing ability to all tested SARS-CoV-2 variants of concern. Single dosing of ISH0339 showed potent neutralizing activity for treatment via intravenous injection and for prophylaxis via nasal spray. Preclinical studies following single dosing of ISH0339 showed favorable pharmacokinetics and well-tolerated toxicology profile.ISH0339 has demonstrated a favorable safety profile and potent anti-SARS-CoV-2 activities against all current variants of concern. Furthermore, prophylactic and therapeutic application of ISH0339 significantly reduced the viral titer in lungs. Investigational New Drug studies to evaluate the safety, tolerability and preliminary efficacy of ISH0339 for both prophylactic and therapeutic purposes against SARS-CoV-2 infection have been filed." @default.
• W4323352010 created "2023-03-08" @default.
• W4323352010 creator A5016894561 @default.
• W4323352010 creator A5019778989 @default.
• W4323352010 creator A5022348147 @default.
• W4323352010 creator A5023652593 @default.
• W4323352010 creator A5024444931 @default.
• W4323352010 creator A5025915502 @default.
• W4323352010 creator A5026329361 @default.
• W4323352010 creator A5028169886 @default.
• W4323352010 creator A5032882849 @default.
• W4323352010 creator A5041833090 @default.
• W4323352010 creator A5051510047 @default.
• W4323352010 creator A5054538110 @default.
• W4323352010 creator A5061140388 @default.
• W4323352010 creator A5071855419 @default.
• W4323352010 creator A5080241467 @default.
• W4323352010 creator A5090808847 @default.
• W4323352010 date "2023-03-06" @default.
• W4323352010 modified "2023-10-18" @default.
• W4323352010 title "Preclinical evaluation of ISH0339, a tetravalent broadly neutralizing bispecific antibody against SARS-CoV-2 with long-term protection" @default.
• W4323352010 cites W2136782733 @default.
• W4323352010 cites W3024602798 @default.
• W4323352010 cites W3033207790 @default.
• W4323352010 cites W3082568883 @default.
• W4323352010 cites W3087511265 @default.
• W4323352010 cites W3092403777 @default.
• W4323352010 cites W3137049262 @default.
• W4323352010 cites W3155123963 @default.
• W4323352010 cites W3165032628 @default.
• W4323352010 cites W3175562186 @default.
• W4323352010 cites W3176646398 @default.
• W4323352010 cites W3193373639 @default.
• W4323352010 cites W3193684745 @default.
• W4323352010 cites W3194865946 @default.
• W4323352010 cites W3208943416 @default.
• W4323352010 cites W4206153788 @default.
• W4323352010 cites W4214772536 @default.
• W4323352010 cites W4226051317 @default.
• W4323352010 cites W4226491433 @default.
• W4323352010 cites W4283034769 @default.
• W4323352010 cites W4295079698 @default.
• W4323352010 cites W4295900705 @default.
• W4323352010 cites W4309686974 @default.
• W4323352010 cites W4310828358 @default.
• W4323352010 cites W4313488719 @default.
• W4323352010 cites W4320728217 @default.
• W4323352010 cites W4321112414 @default.
• W4323352010 doi "https://doi.org/10.1093/abt/tbad003" @default.
• W4323352010 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37077474" @default.
• W4323352010 hasPublicationYear "2023" @default.
• W4323352010 type Work @default.
• W4323352010 citedByCount "0" @default.
• W4323352010 crossrefType "journal-article" @default.
• W4323352010 hasAuthorship W4323352010A5016894561 @default.
• W4323352010 hasAuthorship W4323352010A5019778989 @default.
• W4323352010 hasAuthorship W4323352010A5022348147 @default.
• W4323352010 hasAuthorship W4323352010A5023652593 @default.
• W4323352010 hasAuthorship W4323352010A5024444931 @default.
• W4323352010 hasAuthorship W4323352010A5025915502 @default.
• W4323352010 hasAuthorship W4323352010A5026329361 @default.
• W4323352010 hasAuthorship W4323352010A5028169886 @default.
• W4323352010 hasAuthorship W4323352010A5032882849 @default.
• W4323352010 hasAuthorship W4323352010A5041833090 @default.
• W4323352010 hasAuthorship W4323352010A5051510047 @default.
• W4323352010 hasAuthorship W4323352010A5054538110 @default.
• W4323352010 hasAuthorship W4323352010A5061140388 @default.
• W4323352010 hasAuthorship W4323352010A5071855419 @default.
• W4323352010 hasAuthorship W4323352010A5080241467 @default.
• W4323352010 hasAuthorship W4323352010A5090808847 @default.
• W4323352010 hasBestOaLocation W43233520101 @default.
• W4323352010 hasConcept C112705442 @default.
• W4323352010 hasConcept C126322002 @default.
• W4323352010 hasConcept C14086860 @default.
• W4323352010 hasConcept C159047783 @default.
• W4323352010 hasConcept C159654299 @default.
• W4323352010 hasConcept C195616568 @default.
• W4323352010 hasConcept C197934379 @default.
• W4323352010 hasConcept C203014093 @default.
• W4323352010 hasConcept C2778375690 @default.
• W4323352010 hasConcept C2779134260 @default.
• W4323352010 hasConcept C2779261636 @default.
• W4323352010 hasConcept C3007834351 @default.
• W4323352010 hasConcept C3008058167 @default.
• W4323352010 hasConcept C3020495827 @default.
• W4323352010 hasConcept C524204448 @default.
• W4323352010 hasConcept C542903549 @default.
• W4323352010 hasConcept C71924100 @default.
• W4323352010 hasConcept C98274493 @default.
• W4323352010 hasConceptScore W4323352010C112705442 @default.
• W4323352010 hasConceptScore W4323352010C126322002 @default.
• W4323352010 hasConceptScore W4323352010C14086860 @default.
• W4323352010 hasConceptScore W4323352010C159047783 @default.
• W4323352010 hasConceptScore W4323352010C159654299 @default.
• W4323352010 hasConceptScore W4323352010C195616568 @default.
• W4323352010 hasConceptScore W4323352010C197934379 @default.
• W4323352010 hasConceptScore W4323352010C203014093 @default.
• W4323352010 hasConceptScore W4323352010C2778375690 @default.

• next